FDA Calendar

PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our premium biotech research product and our biotech home page.
Company Name
VivaGel (NDA)
FDA decision on VivaGel for bacterial vaginosis and prevention of recurrent bacterial vaginosis
Early Jan 2019
Portola Pharmaceuticals Inc.
Andexxa Prior Approval Supplement
FDA decision on Andexxa for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed
Bristol-Myers Squibb Co.
Sprycel (sBLA)
FDA decision on Sprycel in combination with chemotherapy for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
FDA approved Sprycel on Jan 2
Merck & Co Inc.
Keytruda (sBLA)
FDA decision on proposed new indication for Keytruda for recurrent locally advanced or metastatic Merkel cell carcinoma
FDA Approves KEYTRUDA on Dec 19
Ocular Therapeutix Inc.
Dextenza (Resubmission NDA)
FDA decision on Dextenza for ocular pain following ophthalmic surgery
Bristol-Myers Squibb Co.
Empliciti (sBLA)
FDA decision on Empliciti in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma
FDA approved Empliciti plus Pomalidomide and Dexamethasone for multiple myeloma on Nov.6, 2018
Roche Holding AG
Baloxavir Marboxil (NDA)
FDA decision on Baloxavir Marboxil for the treatment of acute, uncomplicated influenza in people 12 years and older
Shire plc
Prucalopride (NDA)
FDA decision on Prucalopride as a potential once-daily treatment option for chronic idiopathic constipation in adults
FDA Approves Motegrity (Prucalopride) on Dec 17
Jazz Pharmaceuticals plc
Solriamfetol (NDA)
FDA decision on Solriamfetol for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
FDA decision extended to March 20, 2019
BIVIGAM (Prior Approval Supplement)
FDA decision on BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency
FDA turns down its Prior Approval Supplement filing related to BIVIGAM; reported on Dec 19
Roche Holding AG
FDA decision on TECENTRIQ in combination with Avastin or bevacizumab, paclitaxel and carboplatin or chemotherapy for initial treatment of people with metastatic NSCLC
Catalyst Pharmaceutical Partners Inc.
Firdapse (resubmitted NDA)
FDA decision on Firdapse for Lambert-Eaton myasthenic syndrome (LEMS)
FDA approved Firdapse
Loxo Oncology, Inc.
Larotrectinib NDA
FDA decision on Larotrectinib for patients with locally advanced or metastatic solid tumors harboring NTRK gene fusion
FDA approves Larotrectinib, under brand name Vitrakvi
Aquestive Therapeutics Inc.
AQST-119 (NDA)
FDA decision on AQST-119 for erectile dysfunction
FDA rejects NDA for tadalafil oral film on Nov 16
Mallinckrodt plc
MNK-812(505(b)2 NDA)
FDA decision on MNK-812 for management of pain severe enough to require opioid analgesic

pharma-021618_17jan19.jpg Today's Daily Dose brings you news about FDA thumbs down on Immunomedics' breast cancer drug; FDA panel vote on Sanofi/Lexicon's diabetes drug; progress in Zymeworks/ Lilly collaboration; and encouraging data from Zafgen's diabetes trial.
pharma-021218_17jan19.jpg Today's Daily Dose brings you news about Alder Biopharma's after-hours stock movement; Mirati's stock offering; FDA panel recommendation of Amgen/UCB's osteoporosis drug Evenity; and Pain Therapeutics' grant award.
pharma-022818_15jan19.jpg Today's Daily Dose brings you news about the approval of the world's first device for treatment of premature babies and newborns with an opening in their hearts; the impact of the U.S. government shutdown on Aimmune Therapeutics; Array's BEACON CRC trial results; and Exelixis' expanded FDA approval for Cabometyx tablets.
Read More
Maryland-based Flying Dog Brewery is partnering with cannabis provider Green Leaf Medical Cannabis on a plan to release Maryland's first THC-infused beer in 2019. Flying Dog said in a press release that the beer, a non-alcoholic India Pale Ale named Hop Chronic, will serve as a medical delivery system...
The societal perception of cannabis has undergone a drastic shift, as can be seen from the number of countries jumping on the marijuana legalization bandwagon. Amid this changing scenario, a new study has found that recreational cannabis use, especially in the adolescent period, can bring about structural differences in the brain.
Governor Andrew Cuomo has revealed details of his proposal to legalize recreational marijuana in New York, during a budget address on Tuesday. Cuomo's $175 billion state budget proposal includes his recreational marijuana plan. The budget proposal is for the new fiscal year, which begins on April...
Read More